FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912119952> ?p ?o ?g. }

• W2912119952 endingPage "268" @default.
• W2912119952 startingPage "255" @default.
• W2912119952 abstract "Invasive candidiasis (IC) can be a life-threatening infection in immunocompromised patients, particularly those with cancer, hematologic diseases and/or hematopoietic stem cell transplantation (HSCT) recipients. The objective of this study was to evaluate the effectiveness of micafungin in patients with hematologic malignancies or HSCT recipients, relevant to clinical presentation of IC, in real-life practice in Greece. ASPIRE was a phase IV, multicenter, non-interventional, prospective cohort study, conducted at ten tertiary hospitals in Greece, in adults with hematologic disease. Micafungin treatment for IC or prophylaxis for Candida infection was administered per standard clinical practice until a clinical outcome (success or failure) was reached. Treatment success was defined by the EORTC/MSG criteria for invasive fungal infections (IFI) and was assessed by the investigator. Treatment discontinuation and safety were also evaluated. One hundred forty-three patients were enrolled. Median age was 62; 85 (59.4%) patients were male, and 133 (93.0%) had Greek ethnicity. One hundred twenty-six (88.1%) patients had hematologic malignancies, and 21 (14.7%) had received HSCT. Prophylaxis was administered to 74 (51.7%) patients [median (range) dose: 50 (50–150) mg/day] with no signs of IFI. Overall, 52 (36.4%) patients with possible IFI at baseline received micafungin treatment [100 (50–125) mg/day] versus 12 (17.2%) with probable [100 (75–150) mg/day] and 5 (3.5%) with confirmed [125 (100–150) mg/day] IFI. Treatment success was 91.6% (95% CI 85.80–95.59; n = 131) overall and 90.5% (n = 67) in patients receiving prophylaxis. Median time on treatment was 13 days. Treatment discontinuation (n = 26; 18.2%) was not related to adverse events. No treatment-related serious adverse events were reported. Micafungin treatment for IC or prophylaxis for Candida infection was effective and well tolerated in patients with hematologic disorders in clinical practice in Greece. These results demonstrate that micafungin could be used more widely for prophylaxis. Further work is required to determine the efficacy and safety of micafungin for the management of IFIs in hematologic settings. Astellas Pharma Inc." @default.
• W2912119952 created "2019-02-21" @default.
• W2912119952 creator A5018033667 @default.
• W2912119952 creator A5021449132 @default.
• W2912119952 creator A5041441318 @default.
• W2912119952 creator A5046082476 @default.
• W2912119952 creator A5046487117 @default.
• W2912119952 creator A5050806596 @default.
• W2912119952 creator A5053834889 @default.
• W2912119952 creator A5060469336 @default.
• W2912119952 creator A5068540445 @default.
• W2912119952 creator A5068780868 @default.
• W2912119952 creator A5078995254 @default.
• W2912119952 creator A5090752890 @default.
• W2912119952 date "2019-02-14" @default.
• W2912119952 modified "2023-10-16" @default.
• W2912119952 title "Effectiveness and Safety of Micafungin in Managing Invasive Fungal Infections among Patients in Greece with Hematologic Disorders: The ASPIRE Study" @default.
• W2912119952 cites W1528565239 @default.
• W2912119952 cites W1800819261 @default.
• W2912119952 cites W1857969962 @default.
• W2912119952 cites W1909349784 @default.
• W2912119952 cites W1946090000 @default.
• W2912119952 cites W1976941151 @default.
• W2912119952 cites W1982268275 @default.
• W2912119952 cites W2011695210 @default.
• W2912119952 cites W2022905331 @default.
• W2912119952 cites W2028652300 @default.
• W2912119952 cites W2037989399 @default.
• W2912119952 cites W2040155027 @default.
• W2912119952 cites W2042705599 @default.
• W2912119952 cites W2047037815 @default.
• W2912119952 cites W2054205981 @default.
• W2912119952 cites W2072639782 @default.
• W2912119952 cites W2092492702 @default.
• W2912119952 cites W2092769417 @default.
• W2912119952 cites W2093920981 @default.
• W2912119952 cites W2099536314 @default.
• W2912119952 cites W2099951777 @default.
• W2912119952 cites W2100382166 @default.
• W2912119952 cites W2116837841 @default.
• W2912119952 cites W2121247465 @default.
• W2912119952 cites W2133328722 @default.
• W2912119952 cites W2134002119 @default.
• W2912119952 cites W2138426885 @default.
• W2912119952 cites W2139043187 @default.
• W2912119952 cites W2141563676 @default.
• W2912119952 cites W2156803121 @default.
• W2912119952 cites W2163845781 @default.
• W2912119952 cites W2166734004 @default.
• W2912119952 cites W2167221020 @default.
• W2912119952 cites W2167412063 @default.
• W2912119952 cites W2173441685 @default.
• W2912119952 cites W2216117396 @default.
• W2912119952 cites W2228154648 @default.
• W2912119952 cites W2260819425 @default.
• W2912119952 cites W2339888778 @default.
• W2912119952 cites W2467779100 @default.
• W2912119952 cites W4253534765 @default.
• W2912119952 cites W4254102874 @default.
• W2912119952 cites W2029373666 @default.
• W2912119952 doi "https://doi.org/10.1007/s40121-019-0236-3" @default.
• W2912119952 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6522581" @default.
• W2912119952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30767170" @default.
• W2912119952 hasPublicationYear "2019" @default.
• W2912119952 type Work @default.
• W2912119952 sameAs 2912119952 @default.
• W2912119952 citedByCount "3" @default.
• W2912119952 countsByYear W29121199522019 @default.
• W2912119952 countsByYear W29121199522020 @default.
• W2912119952 countsByYear W29121199522023 @default.
• W2912119952 crossrefType "journal-article" @default.
• W2912119952 hasAuthorship W2912119952A5018033667 @default.
• W2912119952 hasAuthorship W2912119952A5021449132 @default.
• W2912119952 hasAuthorship W2912119952A5041441318 @default.
• W2912119952 hasAuthorship W2912119952A5046082476 @default.
• W2912119952 hasAuthorship W2912119952A5046487117 @default.
• W2912119952 hasAuthorship W2912119952A5050806596 @default.
• W2912119952 hasAuthorship W2912119952A5053834889 @default.
• W2912119952 hasAuthorship W2912119952A5060469336 @default.
• W2912119952 hasAuthorship W2912119952A5068540445 @default.
• W2912119952 hasAuthorship W2912119952A5068780868 @default.
• W2912119952 hasAuthorship W2912119952A5078995254 @default.
• W2912119952 hasAuthorship W2912119952A5090752890 @default.
• W2912119952 hasBestOaLocation W29121199521 @default.
• W2912119952 hasConcept C126322002 @default.
• W2912119952 hasConcept C16005928 @default.
• W2912119952 hasConcept C2777408962 @default.
• W2912119952 hasConcept C2778715236 @default.
• W2912119952 hasConcept C2779020398 @default.
• W2912119952 hasConcept C2779320740 @default.
• W2912119952 hasConcept C2779548794 @default.
• W2912119952 hasConcept C2780651595 @default.
• W2912119952 hasConcept C2911091166 @default.
• W2912119952 hasConcept C71924100 @default.
• W2912119952 hasConceptScore W2912119952C126322002 @default.
• W2912119952 hasConceptScore W2912119952C16005928 @default.
• W2912119952 hasConceptScore W2912119952C2777408962 @default.
• W2912119952 hasConceptScore W2912119952C2778715236 @default.

• next